GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » GlaxoSmithKline Pharmaceuticals Ltd (NSE:GLAXO) » Definitions » Cash And Cash Equivalents

GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Cash And Cash Equivalents : ₹5,389 Mil (As of Mar. 2025)


View and export this data going back to 2000. Start your Free Trial

What is GlaxoSmithKline Pharmaceuticals Cash And Cash Equivalents?

GlaxoSmithKline Pharmaceuticals's quarterly cash and cash equivalents declined from Sep. 2024 (₹492.60 Mil) to Dec. 2024 (₹0.00 Mil) but then increased from Dec. 2024 (₹0.00 Mil) to Mar. 2025 (₹5,388.50 Mil).

GlaxoSmithKline Pharmaceuticals's annual cash and cash equivalents increased from Mar. 2023 (₹349.41 Mil) to Mar. 2024 (₹641.71 Mil) and increased from Mar. 2024 (₹641.71 Mil) to Mar. 2025 (₹5,388.50 Mil).


GlaxoSmithKline Pharmaceuticals Cash And Cash Equivalents Historical Data

The historical data trend for GlaxoSmithKline Pharmaceuticals's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlaxoSmithKline Pharmaceuticals Cash And Cash Equivalents Chart

GlaxoSmithKline Pharmaceuticals Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Cash And Cash Equivalents
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4,051.89 2,861.87 349.41 641.71 5,388.50

GlaxoSmithKline Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cash And Cash Equivalents Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 641.71 - 492.60 - 5,388.50

GlaxoSmithKline Pharmaceuticals Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.


GlaxoSmithKline Pharmaceuticals  (NSE:GLAXO) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.


GlaxoSmithKline Pharmaceuticals Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of GlaxoSmithKline Pharmaceuticals's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.


GlaxoSmithKline Pharmaceuticals Business Description

Traded in Other Exchanges
Address
Dr. Annie Besant Road, GSK House, Worli, Mumbai, MH, IND, 400030
GlaxoSmithKline Pharmaceuticals Ltd is an India-based subsidiary of GlaxoSmithKline plc. GSK India develops and manufactures medicines, vaccines, and consumer products. Its medicines portfolio includes prescription drugs for conditions that include asthma, infectious diseases, mental health, and digestion, as well as nonprescription nutrition and cosmetic products. Its vaccines product line includes treatments for conditions such as influenza, HPV, hepatitis, and measles. Its consumer healthcare products include Horlicks-brand packaged food and beverage powders among other retail products. The company derives majority of its revenue from India.

GlaxoSmithKline Pharmaceuticals Headlines

No Headlines